发明授权
EP2040725B1 TARGETED DELIVERY OF DRUGS, THERAPEUTIC NUCLEIC ACIDS AND FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA INTACT KILLED BACTERIAL CELLS
有权
活性物质,治疗性核酸和功能核酸的哺乳动物细胞靶向给药使用完整杀死的细菌细胞
- 专利标题: TARGETED DELIVERY OF DRUGS, THERAPEUTIC NUCLEIC ACIDS AND FUNCTIONAL NUCLEIC ACIDS TO MAMMALIAN CELLS VIA INTACT KILLED BACTERIAL CELLS
- 专利标题(中): 活性物质,治疗性核酸和功能核酸的哺乳动物细胞靶向给药使用完整杀死的细菌细胞
-
申请号: EP07825666.6申请日: 2007-06-20
-
公开(公告)号: EP2040725B1公开(公告)日: 2014-01-15
- 发明人: BRAHMBHATT, Himanshu , MACDIARMID, Jennifer
- 申请人: EnGeneIC Molecular Delivery Pty Ltd.
- 申请人地址: 105 Delhi Road, Riverside Corporate Park North Ryde, Sydney NSW 2113 AU
- 专利权人: EnGeneIC Molecular Delivery Pty Ltd.
- 当前专利权人: EnGeneIC Molecular Delivery Pty Ltd.
- 当前专利权人地址: 105 Delhi Road, Riverside Corporate Park North Ryde, Sydney NSW 2113 AU
- 代理机构: Plougmann & Vingtoft A/S
- 优先权: US815883P 20060623; US909078P 20070330
- 国际公布: WO2008012695 20080131
- 主分类号: A61K35/74
- IPC分类号: A61K35/74 ; A61K31/7105 ; A61K31/713 ; A61K31/7088 ; A61K31/711 ; A61P35/00
摘要:
A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
公开/授权文献
信息查询